Siolta Therapeutics is focused on treating inflammatory and allergic diseases via live biotherapeutics (LBTs) to improve the functioning of the gut microbiome. They are working to develop bacterial consortia that can be delivered orally. The company is a spinout of UC San Fransisco.

The company's lead product is an LBT to treat allergic diseases and allergic asthma. The company is also developing an LBT to address inflammatory conditions.

Additionally the company is developing diagnostics that can be used to evaluate infant microbiomes and determine what might be missing from the consortia, and for which diseases this might raise the infant's risk. Needed LBTs could then be supplied to address the infant microbiome.

Two of Siolta's founders Susan Lynch and Nikole Kimes are experienced research scientists from UC San Francisco.

Another company working in the microbiome arena has taken a different route than most in the space. CoreBiome provides services to other companies and research departments studying the microbiome. CoreBiome provides fast, accurate genomic profiles of microbial communities (microbiomes) to customers in pharmaceutical, agriculture, and academic research. The company uses proprietary reagents and informatics to provide fast, accurate measurement of microbial diversity.

The Core team includes scientists with expertise in informatics, biology, genetics, and mathematics. They have developed an analysis platform that incorporates big data capabilities to identify key species and genes in biome samples.

To help users easily learn more about microbiome related companies and therapies, we created a microbiome company database. The database includes companies (we add companies regularly and we hope to include all companies working in this space) and products they are developing or currently offer. Access to the database is free for our premium newsletter subscribers. Database only access can be purchased also. Subscriptions can be purchased here.